This company has been marked as potentially delisted and may not be actively trading. NASDAQ:AKRO Akero Therapeutics (AKRO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsFDA EventsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock About Akero Therapeutics Stock (NASDAQ:AKRO) Get Akero Therapeutics alerts:Sign Up Key Stats Today's Range$54.37▼$54.8350-Day Range$53.91▼$54.6952-Week Range$37.28▼$57.35Volume15.31 million shsAverage Volume1.86 million shsMarket Capitalization$4.50 billionP/E RatioN/ADividend YieldN/APrice Target$60.80Consensus RatingHold Company Overview Akero Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for severe metabolic diseases, with an initial emphasis on nonalcoholic steatohepatitis (NASH). The company’s research platform leverages engineered versions of endocrine hormones to target key pathways involved in lipid metabolism, glucose regulation and tissue fibrosis. By harnessing the biology of fibroblast growth factor 21 (FGF21), Akero aims to address underlying drivers of metabolic dysfunction rather than merely treating symptoms. The company’s lead product candidate, efruxifermin, is an Fc-FGF21 fusion protein designed to improve liver health and metabolic parameters in patients with NASH. Efruxifermin has demonstrated reductions in liver fat content, improvements in markers of liver injury and favorable changes in lipid and glucose profiles in early-phase clinical studies. Akero is advancing efruxifermin through pivotal trials, including global Phase 2 and Phase 3 studies, with the goal of achieving regulatory approval for patients with advanced liver fibrosis due to NASH. Founded in 2017 and headquartered in Boston, Massachusetts, Akero Therapeutics operates research and development facilities in North America while engaging clinical sites across the United States and Europe. The company’s scientific leadership comprises experts in metabolic disease biology, protein engineering and drug development, supported by advisory collaborations with leading academic institutions. Akero’s board includes seasoned biotech investors and executives who guide its strategic direction. In addition to its lead program, Akero is exploring preclinical candidates that modulate other hormone pathways implicated in cardiometabolic and fibrotic disorders. Through partnerships with contract research organizations and regulatory agencies, the company aims to expand its pipeline and ultimately deliver new treatment options for patients suffering from metabolic and liver diseases worldwide.AI Generated. May Contain Errors. Read More Akero Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks7th Percentile Overall ScoreAKRO MarketRank™: Akero Therapeutics scored higher than 7% of companies evaluated by MarketBeat, and ranked 835th out of 858 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.0 / 5Analyst RatingHold Consensus RatingAkero Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.10, and is based on no strong buy ratings, 2 buy ratings, 7 hold ratings, and 1 sell rating.Upside PotentialAkero Therapeutics has a consensus price target of $60.80, representing about 11.3% upside from its current price of $54.65.Amount of Analyst CoverageAkero Therapeutics has received no research coverage in the past 90 days.Read more about Akero Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Akero Therapeutics are expected to decrease in the coming year, from ($3.99) to ($4.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Akero Therapeutics is -28.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Akero Therapeutics is -28.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAkero Therapeutics has a P/B Ratio of 5.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for AKRO. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAkero Therapeutics does not currently pay a dividend.Dividend GrowthAkero Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows1 people have added Akero Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Akero Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders7.07% of the stock of Akero Therapeutics is held by insiders.Percentage Held by InstitutionsAkero Therapeutics has minimal institutional ownership at this time.Read more about Akero Therapeutics' insider trading history. Receive AKRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akero Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AKRO Stock News HeadlinesNovo Nordisk has completed its acquisition of Akero TherapeuticsDecember 9, 2025 | globenewswire.comAkero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc. - AKRONovember 20, 2025 | businesswire.comSystem failure: The strongest leverage for gold…$9 trillion in U.S. debt must be refinanced in 2026 - at current rates - while the largest foreign buyers of Treasuries are stepping back. That leaves the Fed with one real option: print. Gold is already trading around $4,500, but many miners are still priced as if gold were under $2,000. Garrett Goggin, CFA and CMT, has identified four miners positioned to close that gap.May 22 at 1:00 AM | Golden Portfolio (Ad)Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO)November 12, 2025 | prnewswire.comAkero Therapeutics (AKRO): Examining Valuation After Strong Year-to-Date Share Price GainsNovember 10, 2025 | finance.yahoo.comAkero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025November 7, 2025 | globenewswire.comBerger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO)November 4, 2025 | prnewswire.comAkero Therapeutics (AKRO) Price Target Decreased by 15.18% to 64.26October 29, 2025 | msn.comSee More Headlines AKRO Stock Analysis - Frequently Asked Questions How were Akero Therapeutics' earnings last quarter? Akero Therapeutics, Inc. (NASDAQ:AKRO) issued its earnings results on Friday, November, 7th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.94) by $0.05. When did Akero Therapeutics IPO? Akero Therapeutics (AKRO) raised $86 million in an initial public offering (IPO) on Thursday, June 20th 2019. The company issued 5,750,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and Evercore ISI acted as the underwriters for the IPO and Roth Capital Partners was co-manager. What other stocks do shareholders of Akero Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Akero Therapeutics investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD). Company Calendar Last Earnings11/07/2025Today5/22/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AKRO CIK1744659 Webwww.akerotx.com Phone(650) 487-6488FaxN/AEmployees30Year Founded2017Price Target and Rating Average Price Target for Akero Therapeutics$60.80 High Price Target$76.00 Low Price Target$54.00 Potential Upside/Downside+11.3%Consensus RatingHold Rating Score (0-4)2.10 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($1.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$252.06 million Net MarginsN/A Pretax MarginN/A Return on Equity-15.86% Return on Assets-14.78% Debt Debt-to-Equity RatioN/A Current Ratio15.84 Quick Ratio15.83 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$10.75 per share Price / Book5.08Miscellaneous Outstanding Shares82,320,000Free Float76,504,000Market Cap$4.50 billion OptionableOptionable Beta-0.40 Social Links 5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:AKRO) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersSystem failure: The strongest leverage for gold…$9 trillion in U.S. debt must be refinanced in 2026 - at current rates - while the largest foreign buyers of T...Golden Portfolio | SponsoredI had never heard of this 1888 accountAn investment account dating back to 1888 has quietly delivered average annual returns of 29% over the last 25...The Oxford Club | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredSpaceX controls two-thirds of all satellites - and it is about to go publicSpaceX is targeting an IPO on June 11th, with trading set to begin June 12th and the roadshow kicking off June...NXT Wave Research | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredHow to Profit from Elon’s AI lab before it goes publicElon Musk's AI lab has partnered with the Department of Defense, Oracle, and Palantir - and he just filed conf...InvestorPlace | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
